Alboni P, Razzolini R et al.
Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation.
J Am Coll Cardiol 1993; 22(5): 1373-1377.

Amiodarone vs Sotalol Study Group. Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias.
Eur Heart J 1989; 10: 685-694.

Anastasiou-Nana MI, Gilbert EM et al.
Uselfulness of dl sotalol for suppression of chronic ventricular arrhythmias.
Am J Cardiol 1991; 67: 511-516.

Beaufort-Krol GCM, Bink-Boelkens MThE.
Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease.
Am J Cardiol 1997; 79: 92-94.

Blair AD, Burgess ED et al.
Sotalol kinetics in renal insufficiency.
Clin Pharmacol Ther 1981; 29:457-463.

Bocker D, Haverkamp W et al.
Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
Circulation 1996; 94: 151-157.

Borggrefe M, Breithardt G.
Electrophysiologic effect of sotalol in supraventricular tachycardias.
Z Kardiol 1985; 74(9): 506-511.

Burckhardt D, Pfisterer M et al.
Effects of the beta-adrenoceptor blocking agent sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease.
Cardiology 1983; 70(Suppl. 1): 114-121.

Camm AJ, Paul V.
Sotalol for paroxysmal supraventricular tachycardias.
Am J Cardiol 1990; 65(2): 67A-73A.

Dorian P, Newman D.
Effect of sotalol on ventricular fibrillation and defibrillation in humans.
Am J Cardiol 1993; 72 (suppl): 72A-79A.

Dumas M, D’Athis P et al.
Variations of sotalol kinetics in renal insufficiency.
Int J Clin Pharmacol Ther Toxicol 1989; 27: 486-489.

Fiset C, Philippon F et al.
Stereoselective disposition of sotalolo at steady-state conditions.
British J of Clin Pharmacol 1993; 36: 75-77

Fiset C, Drolet B et al.
Block of Iks by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol.

Fitton A, Sorkin EM.
Sotalol: an updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 1993; 46: 678-719.

Frisk Holmberg M, Juhlin Dannfelt A et al.
Therapeutic and metabolic effects of sotalol.
Clin Pharmacol Ther 1984; 36: 174-182.

Gallik DM, Kim SG et al.
Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter.
Am Heart J 1997; 134 (2 Pt1): 155-160.

Gill JS, Mehta D et al.
Efficacy of flecainide, sotalol and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.
Br Heart J 1992; 68: 392-397.

Gosse P, Durandet P et al. Effet du sotalol sur la masse et la fonction ventriculaire gauche de l’hypertendu. Arch Mal Coeur 1991; 84: 1823-1826.

Gottlieb SS, Singh S et al.
Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure. Am J Cardiol 1996; 78(12): 1411-1415.

Hackett LP, Wojnar-Horton RE et al.
Excretion of sotalol in breast milk.
Br J Clin Pharmacol 1990; 29: 277-278.

Halinen MO, Huttunen M et al.
Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).
Am J Cardiol 1995; 76(7); 495-498.

Hanyok JJ, MacNeil DJ et al.
Sotalol versus class I and class II antiarrhythmic agents.
Cardiovasc Drugs Ther 1990; 4(suppl): III-603-612.

Haverkamp W, Martinez-Rubio A et al.
Effiacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
J Am Coll Cardiol 1997; 30(2): 487-495.

Ho DS, Zecchin RP et al.
Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia.
Lancet 1994; 344: 18-23.

Hohnloser SH, Zabel M et al.
Short and long term antiarrhythmic and hemodynamic effects of dl-sotalol in patients with symptomatic ventricular arrhythmias.
Am Heart J 1992; 123: 1220-1224.

Hohnloser SH, Arendts W et al.
Torsade de pointes during sotalol therapy.
Eur Heart J 1992b; 13 (suppl):305.

Hohnloser SH, Zabel M et al.
Relation of diurnal variation of ventricular repolarization to ventricular ectopic activity and modification by sotalol.
Am J Cardiol 1993; 71: 475-478.

Hohnloser SH, van de Loo A et al.
Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
J Am Coll Cardiol 1995; 26(4): 852-858.

Hohnloser SH.
Proarrhythmia with class III antiarrhythmic drugs: types, risks and management.
Am J Cardiol 1997; 80(8A): 82G-89G.

Huikuri HV, Koistinen MJ et al.
Efficacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during isometric exercise.
Am J Cardiol 1992; 69(5): 498-502.

Ibrahim MM, Zaghloul SS et al.
Effect of regression of left ventricular hypertrophy following sotalol therapy on diastolic function in hypertensive patients.
J Hyper 1987; 5 (Suppl. 5): S411-S414.

Ishizaki T, Hirayama H et al.
Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug.
J Pharmacol Exp Ther 1980; 212: 173-181.

Jacquet L, Evenepoel M et al.
Efficacy, safety and hemodynamic effects of sotalol in the prevention of supraventricular arrhythmia after coronary artery bypass surgery.
Acta Cardiologica 1991; 46: 255-256.

Janssen J, Loomans L et al.
Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: a randomized open trial.
Angiol 1986; 37: 601-609.

Jordaens L, Gorgels A et al.
Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group.
Am J Cardiol 1991; 68(1): 35-40.

Jordaens LJ, Palmer A et al.
Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Eur Heart J 1989; 10: 218-226.

Jurkiewicz NK, Sanguinetti MC et al.
Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: specific block of rapidly activating delayed rectifier K current by dofetilide.
Circ Res 1993; 72: 75-83.

Julian DG, Prescott RJ et al.
Controlled trial of sotalol for one year after myocardial infarction.
Lancet 1982; 1: 1142-1147.

Juul-Moller S, Edvardsson N et al.
Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.
Circulation 1990; 82: 1932-1939.

Kehoe RF, MacNeil DJ et al.
Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
Am J Cardio 1993; 72(suppl): 56A-66A.

Khalighi K, Peters RW et al.
Comparison of class IA/IB versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease.
Am J Cardiol 1997; 80: 591-594.

Khastgir T, Lattuca J et al.
Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation.
PACE 1991; 14: 768-772.

Kligenheben T, Hohnloser SH.
Effect of sotalol on heart rate variability in patients with symptomatic complex ventricular arrhythmias.
Z Kardiol 1994; 83(4): 293-298.

Kuhlkamp V, Mermi J et al.
Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
Eur Heart J 1995; 16(11): 1625-1631.

Kuhlkamp V, Mermi J et al.
Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
J Cardiovasc Pharmacol 1997; 29(3): 373-381.

Kunze KP, Schluter M et al.
Sotalol in patients with Wolff-Parkinson-White syndrome.
Circulation 1987; 75(5): 1050-1057.

Kuss T, Campa MA et al.
Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Am heart J 1992; 123: 82-89.

Laer S, Neumann J et al.
Interaction between sotalol and antiacid preparation.
Br J Clin Pharmacol 1997; 43(3): 269-272.

Lamaison D, vacher D et al.
Association de diltiazem a liberation prolongee et d’un betabloquant dans l’hypertension arterielle. Deux cas de choc cardiogenique avec bradycardie extreme.
Therapie 1990; 45: 411-413.

Lau CP, Lok NS.
A comparison of transevenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold.
PACE 1997; 20 (10Pt1): 2442-2452.

Lee RJ, Wong M et al.
Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. Am Heart J 1996; 132(5): 973-978.

Lee SD, Newman D et al.
Electrophysiologic mechanism of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
J Am Coll Cardiol 1997; 29(1): 100-105.

Lee SH, Chen SA et al.
Comparison of orla propafenone and sotalol as an initial treatment in patients with symptomatic parxysmal atrial fibrillation.
Am J Cardiol 1997; 79(7): 905-908.

Lehmann MH, Sterling H et al.
Sex differences in risk of torsade de pointes with d,l-sotalol.
Circulation 1996; 94: 2534-2541.

Lengfelder W, Rappert-Plosser B et al.
Sotalol bei ventrikularen arrhythmien.
Munchener Med Wochenschrift 1991; 133: 295-299.

Lidell C, Rehnqvist N et al.
Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study.
Am Heart J 1985; 109: 970-975.

Lloyd EA, Charles RG et al.
Beta-blockade by sotalol in early myocardial infarction decreases ventricular arrhythmias without increasing left ventricular volume.
South African Medical Journal 1988; 74: 5-10.

MacNeil DJ, Davies RO et al.
Clinical safety profile of sotalol in the treatment of arrhythmias.
Am J Cardiol 1993; 72: 44A-50A.

Mahmarian JJ, Verani MS et al.
The emodynamic effects of sotalol and quinidine analysis by use of rest and exercise gated radionuclide angiography.
Circulation 1987; 76: 324-331.

Mahmarian JJ, Verani MS et al.
Hemodynamic effects of intravenous and oral sotalol.
Am J Cardiol 1990; 65: 28A-34A.

Man KC, Williamson BD et al.
Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia.
Am J Cardiol 1994; 74: 1119-1123.

Manz M, Wagner WL et al.
Combination of mexiletine and sotalol in complex ventricular arrhythmias.
ew Trends Arrhyt 1988; 6(suppl):35-41.

Mason JW.
A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias.
N Engl J Med 1993; 329: 445-451.

Mitchell LB, Wyse DG et al.
Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
Circulation 1987; 76(4): 810-818.

National Institutes of Health (NIH) News Release. NHLBI stops arrhythmias study-implantable cardiac defibrillator reduces death. NHLBI communications. April 14; 1997.

Nystrom U, Edvardsson N et al.
Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery.
Thorac Cardiovasc Surg 1993; 41(1): 34-37.

O’Hare MF, Murnaghan GA et al.
Sotalol as a hypotensive agent in pregnancy.
Br J Obstet Gynecol 1980; 87: 814-820.

Paul T, Lehmann C et al.
Ergebnisse der oralen Sotaloltherapie bei Kindern mit supraventrikulaeren und ventrikulaeren Dysrhythmien.
Z Kardiol 1994; 83: 891-897.

Pfammetter JP, Paul T.
New antiarrhythmic drug in pedriatic use: sotalol.
Pediatr Cardiol 1997; 18: 28-34.

Pfisterer ME, Kloter-Weber UC et al.
Prevention of supraventricular tachyarrhythmias after open heart operation by low-dose sotalol: a prospective, double-blind, randomized, placebo-controlled study.
Ann Thorac Surg 1997; 64(4):1113-1119.

Plewan A, Lehmann G et al.
Maintenance of sinus rhythm after cardioversion of atrial fibrillation: sotalol vs bisoprolol.
Circulation 1997; 96 (8): I-201.

Rankin AC, Hamilton L et al.
Predictors of induced arrhythmia suppression and long term efficacy of oral sotalol in patients with drug refractory ventricular arrhythmias.
Br Heart J 1991; 66: 108A.

Reiffel JA, Hahn E et al.
Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure.
Am J Cardiol 1997; 79: 1048-1053.

Reimold SC, Cantillon CO et al.
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Am J Cardiol 1993; 71: 558-563.

Sanguinetti MC, Jurkiewicz NK.
Two components of cardiac delayed rectifier K⁺ current. Differential sensitivity to block by class III antiarrhythmic agents.
J of General Physiol 1990; 96: 195-215.

Schmitt C, Brachmann J et al.
Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle.
Am J Cardiol 1991; 68: 1183-1187.

Schohn DC, Jahn HA et al.
Effets hemodynamiques et metaboliques immediats et a moyen terme du chlorhydrate de sotalol dans le traitement de l’hypertension arterielle compliquant l’insuffisance renale chronique.
Semaine Hop Paris 1989; 65: 2139-2146.

Scott Millar RN.
Efficacy of sotalol in controlling reentrant supraventricular tachycardias.
Cardiovascular Drugs Ther 1990; 4(suppl 3): 625-630.

Singh BN, Deedwania P et al.
Sotalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Drugs 1987; 34: 311-349.

Singh BN, Kehoe R et al.
Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double blind, randomized parallel evaluation.
Am heart J 1995; 129: 87-97.

Singh S, Saini RK et al.
Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation.
Am J Cardiol 1991; 68: 1227-1230.

Singh SN, Chen Y et al.
Relation between ventricular function and antiarrhythmic responses to sotalol.
Am J Cardiol 1989; 64: 943-945.

Soyka LF, Wirtz C et al.
Clinical safety profile of sotalol in patients with arrhythmias.
Am J Cardiol 1990; 65 (Suppl.): 74A-81A.

Sundquist H, Antilla MS et al.
Comparative bioavailability and pharmacokinetics of sotalol alone and in combination with hydrochlorothiazide.
J Clin Pharmacol 1979; 19: 557-564.

Sundquist H.
Basic review and comparison of beta-blocker pharmacokinetics.
Curr Ther Res 1980; 28: 388-448.

Sung RJ, Karagounis L et al.
Intravenous sotalol for the treatment of supraventricular tachyarrhythmias: safety and efficacy.
J Am Coll Cardiol 1992; 19: 220A.

Suttorp MJ, Kingma JH et al.
Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting.
Am J Cardiol 1991; 68: 1163-1169.

Tanel RE, Walsh EP et al.
Sotalol for refractory arrhythmias in pedriatic and young adult patients: initial efficacy and long-term outcome.
Am Heart J 1995; 130: 791-797.

Teo KK, Harte M et al.
Sotalol infusion in the treatment of supraventricular tachyarrhythmias.
Chest 1985; 87: 113-118.

Toubul P, Atallah G et al.
Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties.
Am Heart J 1984; 107: 888-895.

Toubul P, Atallah G et al.
Effects of intravenous sotalol in patients with atrioventricular accessory pathways.
Am Heart J 1987; 114(3): 545-550.

Uematsu T, Kanamaru M et al.
Comparative pharmacokinetics and pharmacodynamic properties of oral and intravenous sotalol in healthy volunteers.
J Pharm Pharmacol 1994; 46: 600-605.

Villemaire C, Taljic M et al.
Mechanism by which sotalol prevents atrial fibrillation at doses that fail to terminate the arrhythmia. Circulation 1997; 96 (8): I-236.

Wagner X, Jouglard J et al.
Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk.
Am Heart J 1990; 119: 700-702.

Waldo AL, Camm AJ et al.
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.
Lancet 1996; 348(9019): 7-12.

Waleffe A, Nzayinambaho K et al.
Mechanism of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol.
Eur Heart J 1989; 10(12): 1084-1089.

Wang M, Dorian P et al.
dl- and d-sotalol decrease defibrillation energy requirements.
PACE 1989; 12: 1522-1529.

Wang T, Bergstrandt RH et al.
Concentration-dependant pharmacologic properties of sotalol.
Am J Cardiol 1986; 57: 1160-1165.

Warren R, Vohra J et al.
Serious interactions of sotalol with amiodarone and flecainide.
Med J Austr 1990; 152: 277.

Wichter T, Borggrefe M et al.
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
Circulation 1992; 86(1): 29-37.

Young GD, Kerr CR et al.
Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
Am J Cardiol 1994; 73: 677-682.

Yusuf S, Peto R et al.
Beta blockade during and after myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis 1985; 27: 335-371.

Indice SOTALOLO / CORRETTO USO